FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2942632018> ?p ?o ?g. }

• W2942632018 endingPage "1065" @default.
• W2942632018 startingPage "1054" @default.
• W2942632018 abstract "Aim This study aimed to investigate the clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma (HCC) after sorafenib treatment. Methods Of 122 patients, 103 were radiologically confirmed as progressive disease (PD) (sorafenib‐refractory group), and 19 discontinued sorafenib therapy due to adverse events prior to radiologic PD (sorafenib‐intolerant group). Patients in the sorafenib‐refractory group were divided into two subgroups each, according to their eligibility for second‐line treatment (second‐line‐in and ‐out group), regorafenib (RESORCE‐in and ‐out group), or ramucirumab (REACH‐2‐in and ‐out group). Results Patients included in the non‐candidate group were those with α‐fetoprotein level <400 ng/mL ( n = 51, 49.5%), daily sorafenib dose <400 mg ( n = 44, 42.7%), Child–Pugh B or C ( n = 40, 38.8%), and Eastern Cooperative Oncology Group performance status score ≥2 ( n = 24, 23.3%). The percentages of candidates were 57.3% for second‐line, 35.0% for regorafenib, and 23.3% for ramucirumab. The median post‐progression survival (PPS) was significantly longer for the second‐line‐in and the RESORCE‐in groups than in the non‐candidate groups (12.6 and 11.0 months vs. 3.0 and 6.1 months, respectively). The PPS was not significantly different between the REACH‐2‐in and ‐out groups. A significant predictor of candidates for second‐line treatment at sorafenib initiation was a Child–Pugh score of 5 (A5). Conclusions Not all patients refractory to sorafenib were candidates for second‐line therapy. A Child–Pugh score of A5 at sorafenib initiation was an important and favorable factor related to eligibility for second‐line therapy and good outcomes." @default.
• W2942632018 created "2019-05-09" @default.
• W2942632018 creator A5007617963 @default.
• W2942632018 creator A5029744979 @default.
• W2942632018 creator A5048728798 @default.
• W2942632018 creator A5056500184 @default.
• W2942632018 creator A5060266231 @default.
• W2942632018 creator A5065828661 @default.
• W2942632018 creator A5078219838 @default.
• W2942632018 creator A5079664647 @default.
• W2942632018 date "2019-05-29" @default.
• W2942632018 modified "2023-10-18" @default.
• W2942632018 title "Clinical characteristics and outcomes of candidates for second‐line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment" @default.
• W2942632018 cites W1739036892 @default.
• W2942632018 cites W1828082159 @default.
• W2942632018 cites W1990623643 @default.
• W2942632018 cites W2054055814 @default.
• W2942632018 cites W2079586464 @default.
• W2942632018 cites W2157942624 @default.
• W2942632018 cites W2236745112 @default.
• W2942632018 cites W2252294506 @default.
• W2942632018 cites W2520083451 @default.
• W2942632018 cites W2531453937 @default.
• W2942632018 cites W2560499218 @default.
• W2942632018 cites W2606367731 @default.
• W2942632018 cites W2755303271 @default.
• W2942632018 cites W2765938943 @default.
• W2942632018 cites W2773914067 @default.
• W2942632018 cites W2784178687 @default.
• W2942632018 cites W2799928024 @default.
• W2942632018 cites W2799933121 @default.
• W2942632018 cites W2801863899 @default.
• W2942632018 cites W2805592007 @default.
• W2942632018 cites W2806175552 @default.
• W2942632018 cites W2809889937 @default.
• W2942632018 cites W2888313539 @default.
• W2942632018 cites W2896734282 @default.
• W2942632018 cites W2898616210 @default.
• W2942632018 cites W2898690597 @default.
• W2942632018 cites W2908573150 @default.
• W2942632018 doi "https://doi.org/10.1111/hepr.13358" @default.
• W2942632018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31033165" @default.
• W2942632018 hasPublicationYear "2019" @default.
• W2942632018 type Work @default.
• W2942632018 sameAs 2942632018 @default.
• W2942632018 citedByCount "37" @default.
• W2942632018 countsByYear W29426320182019 @default.
• W2942632018 countsByYear W29426320182020 @default.
• W2942632018 countsByYear W29426320182021 @default.
• W2942632018 countsByYear W29426320182022 @default.
• W2942632018 countsByYear W29426320182023 @default.
• W2942632018 crossrefType "journal-article" @default.
• W2942632018 hasAuthorship W2942632018A5007617963 @default.
• W2942632018 hasAuthorship W2942632018A5029744979 @default.
• W2942632018 hasAuthorship W2942632018A5048728798 @default.
• W2942632018 hasAuthorship W2942632018A5056500184 @default.
• W2942632018 hasAuthorship W2942632018A5060266231 @default.
• W2942632018 hasAuthorship W2942632018A5065828661 @default.
• W2942632018 hasAuthorship W2942632018A5078219838 @default.
• W2942632018 hasAuthorship W2942632018A5079664647 @default.
• W2942632018 hasConcept C121332964 @default.
• W2942632018 hasConcept C121608353 @default.
• W2942632018 hasConcept C126322002 @default.
• W2942632018 hasConcept C142424586 @default.
• W2942632018 hasConcept C143998085 @default.
• W2942632018 hasConcept C197934379 @default.
• W2942632018 hasConcept C2776248978 @default.
• W2942632018 hasConcept C2778019345 @default.
• W2942632018 hasConcept C2778695046 @default.
• W2942632018 hasConcept C2779551604 @default.
• W2942632018 hasConcept C3018840467 @default.
• W2942632018 hasConcept C3019894029 @default.
• W2942632018 hasConcept C526805850 @default.
• W2942632018 hasConcept C71924100 @default.
• W2942632018 hasConcept C87355193 @default.
• W2942632018 hasConcept C90924648 @default.
• W2942632018 hasConceptScore W2942632018C121332964 @default.
• W2942632018 hasConceptScore W2942632018C121608353 @default.
• W2942632018 hasConceptScore W2942632018C126322002 @default.
• W2942632018 hasConceptScore W2942632018C142424586 @default.
• W2942632018 hasConceptScore W2942632018C143998085 @default.
• W2942632018 hasConceptScore W2942632018C197934379 @default.
• W2942632018 hasConceptScore W2942632018C2776248978 @default.
• W2942632018 hasConceptScore W2942632018C2778019345 @default.
• W2942632018 hasConceptScore W2942632018C2778695046 @default.
• W2942632018 hasConceptScore W2942632018C2779551604 @default.
• W2942632018 hasConceptScore W2942632018C3018840467 @default.
• W2942632018 hasConceptScore W2942632018C3019894029 @default.
• W2942632018 hasConceptScore W2942632018C526805850 @default.
• W2942632018 hasConceptScore W2942632018C71924100 @default.
• W2942632018 hasConceptScore W2942632018C87355193 @default.
• W2942632018 hasConceptScore W2942632018C90924648 @default.
• W2942632018 hasIssue "9" @default.
• W2942632018 hasLocation W29426320181 @default.
• W2942632018 hasLocation W29426320182 @default.
• W2942632018 hasOpenAccess W2942632018 @default.
• W2942632018 hasPrimaryLocation W29426320181 @default.
• W2942632018 hasRelatedWork W2592068656 @default.

• next